Position in SVRA
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$264,810
-$27,687 QoQ
Shares Held
48,500
-0.0% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#99
of 184 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in SVRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Sivia Capital Partners, LLC holds $4,485,324 across 9 Biotechnology names. SVRA ranks #7 (5.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMRN |
Biomarin Pharmaceutical Inc
|
18,420 | $1,040,545 | |
| 2 | EXEL |
Exelixis, Inc.
|
23,984 | $1,028,673 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
4,438 | $839,003 | |
| 4 | INCY |
Incyte Corp
|
5,658 | $532,530 | |
| 5 | RPRX |
Royalty Pharma plc
|
7,479 | $358,767 | |
| 6 | ROIV |
Roivant Sciences Ltd.
|
12,420 | $344,034 | |
| 7 | SVRA |
Savara Inc
This page
|
48,500 | $264,810 | |
| 8 | ZNTL |
Zentalis Pharmaceuticals, Inc.
|
20,000 | $46,800 |
All Filings in SVRA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $264,810 | 48,500 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $292,497 | 48,507 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $173,145 | 48,500 | Shares | Sole | 2025-10-20 | |
| 2025-06-30 | $94,620 | 41,500 | Shares | Sole | 2025-09-24 | |
| 2025-03-31 | $105,373 | 38,041 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $116,660 | 38,000 | Shares | Sole | 2025-01-13 | |
| 2024-09-30 | $171,720 | 40,500 | Shares | Sole | 2024-10-11 | |
| 2024-06-30 | $157,170 | 39,000 | Shares | Sole | 2024-08-05 | |
| 2024-03-31 | $186,750 | 37,500 | Shares | Sole | 2024-04-19 | |
| 2023-12-31 | $169,200 | 36,000 | Shares | Sole | 2024-03-13 | |
| No filing history on record for this holder in this stock. | ||||||